18-Fluorodeoxyglucose positron emission tomography and pancreatic cancer [1]

Digestive Surgery

Volumn 22, Issue 6, 2006, Pages 467-468

  Pedrazzoli, Sergio ^a,c   Pasquali, Claudio ^a   Sperti, Cosimo ^a   Chierichetti, Franca ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b Ospedale di Castelfranco Veneto   (Italy)

^c Dipartimento di Scienze Mediche e Chirurgiche   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; HUMAN; IMAGE ANALYSIS; LETTER; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY;

FLUORODEOXYGLUCOSE F18; HUMANS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY;

EID: 33646083002     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092036     Document Type: Letter

References (14)

1. Lytras D, Connor S, Bosonnet L, Jayan R, Evans J, Hughes M, Garvey CJ, Ghaneh P, Sutton R, Vinjamuri S, Neoptolemos JP: Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer. Dig Surg 2005;22:55-62.
2. Isselbacher KJ: Sugar and amino acid transport by cells in culture - differences between normal and malignant cells. N Engl J Med 1972;286:929-933.
3. Ito H, Duxbury M, Zinner MJ, Ashley SW, Whang EE: Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. Surgery 2004;136:548-556.
4. Nakamoto Y, Saga T, Higashi T, Ishimori T, Kobayashi H, Ishizu K, Sato N, Mamede M, Sakahara H, Imamura M, Konishi J: Optimal scan time for evaluating pancreatic disease with positron emission tomography using F-18-fluorodeoxyglucose. Ann Nucl Med 2003;17:421-426.
5. Delbeke D: Oncological applications of FDG PET imaging. J Nucl Med 1999;40:1706-1715.
6. Reske SN, Kotzerke J: FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, 'Onko-PET III', 21 July and 19 September 2000. Eur J Nucl Med 2001;28:1707-1723.
7. Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN: FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 1998;39:1030-1033.
8. Sperti C, Pasquali C, Chierichetti F, Ferronato A, Decet G, Pedrazzoli S: 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg 2003;7:953-960.
9. Orlando LA, Kulasingam SL, Matchar DB: Meta-analysis: the detection of pancreatic malignancy with positron emission tomography. Aliment Pharmacol Ther 2004;20:1063-1070.
10. Van Kouwen MCA, Jansen JB, van Goor H, de Castro S, Oyen WJ, Drenth JP: FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis. Eur J Nucl Med Mol Imaging 2005;32:399-404.
11. Koyama K, Okamura T, Kawabe J, Nakata B, Hirakawa K, Chung YS, Ochi H, Yamada R: Diagnostic usefulness of FDG PET for pancreatic mass lesions. Ann Nucl Med 2001;15:217-224.
12. Higashi T, Sakahara H, Torizuka T, Nakamoto Y, Kanamori S, Hiraoka M, Imamura M, Nishimura Y, Tamaki N, Konishi J: Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET. J Nucl Med 1999;40:1424-1433.
13. Humm JL, Rosenfeld A, Del Guerra A: From PET detectors to PET scanners. Eur J Nucl Med Mol Imaging 2003;30:1574-1597.
14. Heinrich S, Goerres GW, Schafer M, Sagmeister M, Bauerfeind P, Pestalozzi BC, Hany TF, von Schulthess GK, Clavien PA: Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 2005;242:235-243.